Catalent to open new clinical supply facility in San Diego6 Sep 2019
Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.
Catalent is to invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.
The new 24,257-sq ft facility will offer full clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials. Its capabilities will include clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction, and will include stability chambers.
Located less than a mile from the company’s West Coast early-phase oral drug product development center of excellence, the new facility enhances Catalent’s OptiForm Total Supply service, offering customers fully integrated development, clinical supply manufacturing and distribution. This integrated approach helps customers minimize overall project risks and can significantly reduce the time taken to move a program from development into clinic.
“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies” commented Paul Hegwood, President, Clinical Supply Services. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the US and Canada’s drug development region.”
With sites in the US, UK, Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, and so help to expedite clinical trials by ensuring customers are reliably supplied where and when needed around the globe.
Catalent’s existing San Diego facility is one of three global centers of excellence in oral dose early-phase development focusing on preclinical to clinical Phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being in Somerset, New Jersey and Nottingham, UK.
Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic
10 Sep 2019
Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.Read more
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development
10 Sep 2019
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.Read more
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
Take part in pharma’s largest reputation survey
6 Sep 2019
Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.Read more
BioCity backs world's first Rx to OTC switch incubator
5 Sep 2019
Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.Read more
Velesco Pharma to triple its clinical manufacturing capacity
4 Sep 2019
Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.Read more
Taiwan's biggest CDMO secures FDA approval
3 Sep 2019
Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.Read more
China relaxes import regulations to improve access and availability of affordable medicines
3 Sep 2019
The potential for generics to support the healthcare needs of China is significant.Read more
Dutch company receives €20 million for skin cancer diagnostic test
3 Sep 2019
The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.Read more
Sandoz enters global deal to commercialise proposed biosimilar natalizumab
2 Sep 2019
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation